Composite of magnetic drug carriers with thermo-responsive polymer for controlled drug release

We review innovative methods for treatment of cancer tumor on the basis of nanotechnology and physics to target, monitor and control release of chemotherapeutic agents. Chemotherapy is one of the main methods of treatment for cancer and plays a vital role in clinical practice, but side effects of anticancer drugs are still critical problems. Magnetic nanoparticles can be applied as an effective drug carriers and contrast agents for magnetic resonance imaging (MRI). Since certain nanoparticles have magnetic properties, they can be trapped in tumor during blood circulation by an external magnetic field. Also, polymeric nanoparticles are great candidates to encapsulate anticancer drugs and to control the release profile of drugs in biologic media. We suggest the construction of drug-loaded polymer-coated magnetic (DPM) nanoplatform with the potential for being utilized in medical imaging as well as having controlled drug release properties. Nanoplatform distribution can be monitored by MRI and with clever combination of ultrasound physics and suggested DPM nanoplatform, it would be feasible to increase the rate of drug release (in situ) and drug uptake by cancerous cell. To optimize the level of drug uptake by cancerous cell, the selection of ultrasound frequency and intensity is essential. The development of suggested method could be a new approach against cancer tumor.

Download Full-text

Weibull Modeling of Controlled Drug Release from Ag-PMA Nanosystems

Polymers ◽

10.3390/polym13172897 ◽

2021 ◽

Vol 13 (17) ◽

pp. 2897

Author(s):

Carmelo Corsaro ◽

Giulia Neri ◽

Angela Maria Mezzasalma ◽

Enza Fazio

Keyword(s):

Drug Release ◽

Controlled Drug Release ◽

Drug Carriers ◽

Polymer Chains ◽

Patient Treatment ◽

Release Mechanism ◽

Release Process ◽

Precise Control ◽

Biochemical Processes ◽

Drug Selectivity

Traditional pharmacotherapy suffers from multiple drawbacks that hamper patient treatment such as antibiotic resistances or low drug selectivity and toxicity during systemic applications. Some functional hybrid nanomaterials are designed to handle the drug release process under remote-control. More attention has recently been paid to synthetic polyelectrolytes for their intrinsic properties which allow them to rearrange into compact structures, ideal to be used as drug carriers or probes influencing biochemical processes. The presence of Ag nanoparticles (NPs) in the Poly methyl acrylate (PMA) matrix leads to an enhancement of drug release efficiency, even using a low-power laser whose wavelength is far from the Ag Surface Plasmon Resonance (SPR) peak. Further, compared to the colloids, the nanofiber-based drug delivery system has shown shorter response time and more precise control over the release rate. The efficiency and timing of involved drug release mechanisms has been estimated by the Weibull distribution function, whose parameters indicate that the release mechanism of nanofibers obeys Fick’s first law while a non-Fickian character controlled by diffusion and relaxation of polymer chains occurs in the colloidal phase.

Download Full-text

THE EFFECTS OF MODIFIED CLAY ON CONTROLLED DRUG RELEASE SYSTEMS

STED JOURNAL ◽

10.7251/sted1902001l ◽

2019 ◽

Vol 1 (2) ◽

Author(s):

Davut Lacin ◽

Ayse Zehra Aroguz ◽

Vesna Teoflović ◽

Olga Govedarica ◽

Jelena Pavličević ◽

...

Keyword(s):

Drug Release ◽

Active Substance ◽

Release Kinetics ◽

Controlled Drug Release ◽

Drug Carriers ◽

Ammonium Bromide ◽

Buffer Solutions ◽

Cetyltrimethyl Ammonium ◽

Specific Tissue ◽

Kinetics Of

Recently, controlled drug release systems have been garnering a lot of attention, due to more targeted and effective approach for delivering drugs to a specific tissue. Because of a specific structure and natural abundance, clays are being added to those systems in order to increase its efficiency and minimize costs. In this study, controlled release kinetics of the drug active substance 5-Fluorouracil was studied, using halloysite clay/polymer drug carriers. For this purpose, the halloysite clay was initially modified with cetyltrimethyl ammonium bromide (CTAB). Drug carriers were prepared by adding modified halloysite clays in the mixtures of polyvinyl alcohol (PVA) and sodium alginate. Firstly, the swelling behaviour of the prepared substances was studied in buffer solutions at different pH. The drug release kinetics from the drug carriers, loaded with 5- Fluorouracil, was observed under a UV-spectrophotometer at 266 nm. Release profiles of the active substance were obtained by studying its release in buffer solutions at different pH. The results showed that the prepared drug carriers with modified halloysite clay were suitable for carrying and releasing of the 5-Fluorouracil.

Download Full-text

Liposomes for Pulmonary Drug Delivery: The Role of Formulation and Inhalation Device Design

Current Pharmaceutical Design ◽

10.2174/1381612823666161116114732 ◽

2017 ◽

Vol 23 (3) ◽

pp. 362-372 ◽

Cited By ~ 18

Author(s):

Abdelbary Elhissi

Keyword(s):

Clinical Trials ◽

Drug Release ◽

Controlled Drug Release ◽

Drug Carriers ◽

Device Design ◽

Inhalation Device ◽

Liposome Preparation ◽

Wide Range ◽

Therapeutic Molecules

Liposomes are established drug carriers for inhalation owing to their safety and ability to provide controlled drug release in the lung. These carriers can entrap a wide range of therapeutic molecules for delivery in large volumes to the peripheral airways using medical nebulizers. Pressurized metered inhalers (pMDIs), soft mist inhalers (SMIs) and dry powder inhalers (DPIs) can deliver relatively small quantities of medication to the lung when compared to medical nebulizers which can deliver large volumes using simple liposome preparation techniques. Unfortunately, the shearing provided during nebulization to convert the aqueous liposome dispersions into “respirable” aerosol droplets may exert physical stress on liposome bilayers, causing losses of the originally entrapped drug. The development of successful liposome carriers for inhalation depends on two main factors which are formulation composition and nebulizer design, with the aim of reducing the detrimental effect of shearing on liposome stability and maximizing the deposition of vesicles in the ‘deep lung’. A number of nebulizable liposome formulations have reached clinical trials. For example, Arikace® (liposomal amikacin) and Pulmaquin® (liposomal ciprofloxacin) are antibacterial formulations currently in advanced stages of development. In this review, the role of liposome formulation and inhalation device design on the suitability of liposomes for eliciting controlled drug release in the lung was evaluated. Moreover, the factors contributing to the success of Arikace® in clinical trials were appraised.

Download Full-text